About Biohaven Pharmaceutical
Biohaven Pharmaceutical is a publicly listed company based in New Haven (United States) founded in 2014, and was acquired by Pfizer in May 2022. Therapies for neurological and neuropsychiatric diseases are developed. Biohaven Pharmaceutical has raised $84.1 million across 3 funding rounds from investors including Pfizer, RA Capital and Portage Biotech. Biohaven Pharmaceutical has completed 3 acquisitions, including Channel Bio-Sciences, Kleo Pharmaceuticals and Priorityreviewvoucher. Biohaven Pharmaceutical offers products and services including Nurtec ODT and Zavzpret. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is BIOHAVEN PHARMACEUTICALS INC. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Biohaven Pharmaceutical was founded in 2014 in New Haven, United States, within the biotechnology sector. Therapies targeting neurological and neuropsychiatric conditions are developed by the company. The pipeline includes BHV-0223, a glutamate-modulating agent under FDA review, along with BHV-4157 for spinocerebellar ataxia treatment and SHV-5000i, an NMDA receptor antagonist for post-traumatic stress disorder and treatment-resistant depression. Operations focus on drug development for these areas.
- Total Equity Funding$84.1M (USD)
in 3 rounds
- InvestorsPfizer
& 10 more
- Investments & AcquisitionsChannel Bio-Sciences
& 2 more
- Acquired byPfizer
(May 2022)
Products & Services of Biohaven Pharmaceutical
Biohaven Pharmaceutical offers a comprehensive portfolio of products and services, including Nurtec ODT and Zavzpret.
Oral dissolving tablet for migraine treatment and relief.
Nasal spray option for effective migraine management.
Apps and channels of Biohaven Pharmaceutical
its YouTube channel Biohaven has 1K subscribers and 30 videos.
Videos from Biohaven Pharmaceutical
The most watched videos on Biohaven Pharmaceutical's YouTube channel, Biohaven (1K subscribers). Click a video to play it here.
More on Biohaven.
Funding Insights of Biohaven Pharmaceutical
Biohaven Pharmaceutical has successfully raised a total of $84.1M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84.1M
- Total Rounds 3
- First Round $4.1M
(Aug 2015)
- Investors Count 10
All 3 funding rounds of Biohaven Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | Series C | – | – | ||
| Nov 2016 | $80M | Series C | – | Venrock | |
| Aug 2015 | $4.1M | Series A | – | – |
11 investors in total: 11 institutional.
Investors in Biohaven Pharmaceutical
Biohaven Pharmaceutical has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, RA Capital and Portage Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
A healthcare-focused investment firm supporting innovative company growth. | aperturevp.com | |||
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
| knollcapital.com | ||||
Therapeutics based on Cell Permeable Peptide Platform | 2013 | portagebiotech.com | Tortola, United Kingdom |
Investor details for Biohaven Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biohaven Pharmaceutical
159 people are tracked at Biohaven Pharmaceutical (75 in leadership, 6 in board & advisors, 78 in team).
| Name | Role | Group |
|---|---|---|
Jim Mather | VP, Clinical Operations | Leadership |
Robert Croop | Chief Development Officer, Neurology | Leadership |
Jennifer Madonia | Senior Medical Director | Leadership |
Tracey Douglas | Director, Clinical Quality Compliance | Leadership |
St John Donnie McGrath | Chief of Corporate Strategy & Business Development | Leadership |
Cliff Bechtold | President & GM, Biohaven Ireland, Chief Compliance Officer | Leadership |
Melissa Beiner | Director, R&D | Leadership |
Jon Blaskovich | Director, IT | Leadership |
Michael Bozik | President, Ion Channel Research & Development | Leadership |
Anna Bunin | Senior Director, In Vivo & Translational Biology | Leadership |
John Cahill | Associate Director, Information Technology | Leadership |
Vlad Coric | Chairman & CEO | Leadership |
Warren Volles | General Counsel & Chief Legal Officer | Leadership |
Upender Velaparthi | Senior Director, Chemistry | Leadership |
David Pirman | SVP & Head, Drug Discovery | Leadership |
Matthew Buten | Chief Financial Officer | Leadership |
Bharat Awsare | Senior Medical Director | Leadership |
Hilary Lippoth | Director Clinical Operations | Leadership |
Wenxin Gu | Executive Director, Chemistry | Leadership |
Tim King | Senior Director, Commercial | Leadership |
139 more people are available in the full profile.
Complete people profiles for Biohaven Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Biohaven Pharmaceutical
Biohaven Pharmaceutical is a publicly listed company on the NYSE with ticker symbol BHVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 May 2017
- Listed onNYSE: BHVN
- Listed entityBiohaven Ltd.
- Exchange sectorHealth technology
Investments & Acquisitions by Biohaven Pharmaceutical
Biohaven Pharmaceutical has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Channel Bio-Sciences, Kleo Pharmaceuticals and Priorityreviewvoucher.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Healthcare consulting services are provided to industry clients. | channelbiosciences.com | Hyderabad, India | 2016 | Feb 2022 | $100M | |
Developing a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and infectious diseases | kleopharmaceuticals.com | New Haven, United States | 2015 | Jan 2021 | •••• | |
Priority review vouchers are supplied for expedited drug approvals. | priorityreviewvoucher.org | 0 | Mar 2019 | $105M |
Complete acquisition details for Biohaven Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biohaven Pharmaceutical
8 dated milestones of Biohaven Pharmaceutical across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Biohaven Pharmaceutical is founded.
- Funding First funding round of $4.1M.
- Funding Latest funding round, Series C,.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Priorityreviewvoucher.
- Acquisition Acquires Kleo Pharmaceuticals.
- Acquisition Acquires Channel Bio-Sciences.
- Exit Acquired by Pfizer.
Competitors of Biohaven Pharmaceutical
Biohaven Pharmaceutical has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Biohaven Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Biohaven Pharmaceutical (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biohaven Pharmaceutical
Complete news archive for Biohaven Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biohaven Pharmaceutical
Biohaven Pharmaceutical was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Biohaven Pharmaceutical is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Biohaven Pharmaceutical is a funded company, having raised a total of $84.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.1M, raised on Aug 2015.
Biohaven Pharmaceutical was founded in 2014 in New Haven, United States, within the biotechnology sector. Therapies targeting neurological and neuropsychiatric conditions are developed by the company. The pipeline includes BHV-0223, a glutamate-modulating agent under FDA review, along with BHV-4157 for spinocerebellar ataxia treatment and SHV-5000i, an NMDA receptor antagonist for post-traumatic stress disorder and treatment-resistant depression. Operations focus on drug development for these areas.
Biohaven Pharmaceutical's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Biohaven Pharmaceutical offers Nurtec ODT and Zavzpret.
Yes, Biohaven Pharmaceutical is publicly traded on NYSE under the ticker symbol BHVN.
Biohaven Pharmaceutical has made 3 acquisitions, including Channel Bio-Sciences, Kleo Pharmaceuticals, and Priorityreviewvoucher.
Biohaven Pharmaceutical has 11 investors. Key investors include Pfizer, RA Capital, Portage Biotech, Venrock, and Aisling Capital.
Biohaven Pharmaceutical operates through Biohaven Pharmaceuticals Inc.
Yes. Biohaven Pharmaceutical was acquired by Pfizer in May 2022.